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Results: The MR-linac platform is in the last phase of the 
assessment. At its pre-defined imaging position in the linac 
room, the MR was shimmed and configured to work at peak 
performance. The linac’s radiation beam output was also 
found to be within specifications, being not affected by 
multiple passive exposures (testing over one year) to the 
MR’s magnetic fringe field. A hybrid MR-kV framework is 
under development to enable comprehensive RT tools for MR-
only RT planning, quantification of organ motion (fast 
imaging), in-room treatment guidance, and site specific 
adaptive RT workflows. QC procedures specific to the MR and 
linac integration were also developed for the mapping and 
correction of both scanner-related and patient-induced MR 
image distortions, mutual registration of the MR and linac 
isocenters, B0 mapping for monitoring the MR performance, 
4D MR, and generation of synthetic CT data sets. 
 
Conclusion: Key milestones of the MR and linac integration 
were achieved, supporting the feasibility of the system for 
clinical implementation.  
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Purpose or Objective: Locally advanced lung cancer lacks 
effective treatment options and may require aggressive 
chemo-radiotherapy (RT) with high doses. In the light of the 
RTOG 0617 trial, multi-centre dose escalation trials should 
avoid increasing organ at risk (OAR) toxicity and require strict 
quality assurance (QA). Dose escalation can be performed for 
sub volumes of the tumour by targeting of the most FDG-PET 
avid regions, and the planning target volume (PTV) can be 
reduced by implementing daily soft tissue based image-
guidance and adaptive RT. Incorporating these elements, the 
randomized multi-centre trial NARLAL2 by the Danish 
Oncologic Lung Cancer Group aims at increasing loco-regional 
control at 30 months without increasing toxicity. 
 
Material and Methods: In the standard arm, the PTV is 
treated with a homogenous dose of 66 Gy/33 fractions (fx). In 
the experimental arm, the dose is escalated heterogeneously 
to the FDG-PET avid volumes, with mean doses up to 95 
Gy/33 fx for the most PET active volumes of the primary 
tumour, and 74 Gy/33 fx for malignant lymph nodes ≥ 4 cm3. 
The escalation dose is limited in favour of OAR constraints. A 
standard and an experimental treatment plan are optimized 
for each patient prior to randomization. Dose to the lung in 
the experimental plan is kept similar to the lung dose in the 
standard plan. All enrolment centres were obliged to follow a 
strict QA program consisting of a treatment planning study, a 
soft tissue match and adaptive strategy workshop, and QA for 
PET scanners and FDG-PET volume delineation. In the present 
study, the dose distributions of the first 20 patients are 
analysed. The achieved dose escalation is compared to a 
previously conducted pilot study. 
 
 
 
Results: In the pilot study, the dose escalated FDG-PET avid 
part of tumour (PET GTV-T) and lymph nodes (PET GTV-N) 
received an average mean dose of 91.9 Gy and 72.1 Gy, 
respectively. The combined clinical target volume (CTV-total) 
received an average mean dose of 78.6 Gy. This corresponds 
to a 16 % estimated increase in loco-regional control at 30 
months. For the first 20 patients included, the experimental 
plan achieved an average mean dose of 92.3 Gy (SD 3.7) to 
PET GTV-T. A total of 11 large lymph nodes were escalated to 
an average mean dose of 72.1 Gy (SD 2.7) to PET GTV-N. 
CTV-total obtained an average mean dose of 75.8 Gy (SD 
4.1). Normal tissue doses were similar for the experimental 
and standard plan (Table 1). The maximum dose for the 
standard plans was 72.6 Gy (110%). Higher doses were 
applied for the experimental plans, but only to small volumes 
respecting the strict normal tissue constraints (see figure). 
 
 
 
Conclusion: A dose escalation trial with strict QA has been 
set up. Patient enrolment started January 2015. Analysis of 
the first 20 patients demonstrates that the escalation goals 
were met for the target and that dose to OARs were similar 
for the standard and the experimental treatment plans.  
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